News
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demeetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.
FEATURED STORIES
Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.
Saol Therapeutics is the latest biotech to resubmit for approval of a drug rejected under former FDA Commissioner Marty Makary, following REGENXBIO and Replimune.
Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
It was a relatively quiet week for clinical trial announcements. Here’s a look.
StrideBio, Exicure and Syndax Pharmaceuticals tapped new CEOs.
Novartis reported its full-year financials this week for 2021, and overall, the news was good. Of concern, however, is the company’s Sandoz generics unit.
On Thursday, Unity Biotechnology announced that it is cutting 50% of its workforce, mainly in the research department.
This particular renewal panel discussion took an unexpected turn, focusing on Biogen’s controversial drug.
UCB hit the mark in its Phase III clinical trial assessing zilucoplan, while Vanda failed its late-stage study of tradipitant.
Preclinical models indicate that pairing specific cancer treatments with precision nutritional interventions increased treatment efficacy by as much as 500%.
Data from Phase III ECHELON-1 clinical study conducted with either stage III or stage IV cHL showed consistent improvement in OS across each of the six 28-day cycles completed.
The company indicated that its timeline for an accelerated approval request for its own Alzheimer’s drug, donanemab, was no longer on schedule for the first quarter after the CMS draft guidance.
On Thursday, Intellia announced it had paid Rewrite shareholders $45 million upfront. Additionally, the transaction involved a transfer of $155 million in the form of Intellia common stock and cash.